Merrimack Pharmaceuticals

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDETM (irinotecan liposome injection), was approved by the U.S. FDA on October 22, 2015. With four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry.

Company Growth (employees)
Cambridge, US
Size (employees)
294 (est)-30%
Merrimack Pharmaceuticals was founded in 2000 and is headquartered in Cambridge, US

Key People at Merrimack Pharmaceuticals

Robert J. Mulroy

Robert J. Mulroy

President and Chief Executive Officer, Board of Directors
Ulrik B. Nielsen

Ulrik B. Nielsen

Gary Crocker

Gary Crocker

Peter Laivins

Peter Laivins

Team Member
Edward J. Stewart

Edward J. Stewart

Team Member
William A. Sullivan

William A. Sullivan

Team Member

Merrimack Pharmaceuticals Office Locations

Merrimack Pharmaceuticals has office in Cambridge
Cambridge, US

Merrimack Pharmaceuticals Metrics

Merrimack Pharmaceuticals Summary

Market capitalization

$415.2 m

Closing share price

Merrimack Pharmaceuticals's current market capitalization is $415.2 m.

Merrimack Pharmaceuticals Financials

Merrimack Pharmaceuticals's revenue is $47.8 m in FY, 2013 which is a 53.5% decrease from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$47.8 m$102.8 m$89.3 m$144.3 m

Revenue growth, %


Gross profit

$89.2 m

Operating expense total

$218.8 m


($120.5 m)($66.3 m)($129.6 m)

Net Income

($130.7 m)($83.6 m)($147.8 m)($153.5 m)

Operating cash flow

$27.4 m($29.4 m)$149.9 m

Merrimack Pharmaceuticals Market Value History

Merrimack Pharmaceuticals Online Presence

Merrimack Pharmaceuticals News

Merrimack Pharmaceuticals Company Life

You may also be interested in